Real-world study of breast cancer treatment with pertuzumab biosimilar
Part of Cancer, Skin clinical trials.
This study observes how a biosimilar version of pertuzumab (a targeted breast cancer drug) works in real-world patients. Researchers will track outcomes in patients receiving this drug either before surgery or as a first treatment for advanced breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer (a specific type confirmed by lab testing)
- You are at least 19 years old
- Your doctor has decided to give you a pertuzumab biosimilar as part of your regular care (not as part of another research study)
- Your treatment is either before surgery to shrink the tumor, or as your first treatment for cancer that has spread
- You can commit to at least 6 months of follow-up visits and medical record sharing
- You have not had a severe allergic reaction to pertuzumab in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
This study tests a new combination of two HER2-targeted drugs (trastuzumab and pertuzumab) given after surgery for HER2-positive breast cancer. It looks at whether this combination can help reduce the risk of cancer coming back in people who still had some cancer left after neoadjuvant therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.